Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
CITADEL-205
A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor
- NCT03235544 ↗
- Completed
- Incyte Corporation
- Focused
We haven't built an HCP commentary report on CITADEL-205 (parsaclisib in relapsed or refractory mantle cell lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CITADEL-205 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Lymphoma
- Interventions
- Parsaclisib
- Arms
- Cohort 1: Treatment A (Exposed to Ibrutinib) · Experimental
- Cohort 1: Treatment B (Exposed to Ibrutinib) · Experimental
- Cohort 2: Treatment A (Bruton's Tyrosine Kinase Inhibitor Naïve) · Experimental
- Cohort 2: Treatment B (Bruton's Tyrosine Kinase Inhibitor Naïve) · Experimental
- Enrollment
- 162
- Primary outcomes
- Objective Response Rate (ORR)
- Sponsor
- Incyte Corporation
- Start
- Nov 20, 2017
- Primary completion
- Apr 30, 2024
- Results posted
- Yes
- Registry record
- NCT03235544 · updated Mar 18, 2025